Bing-yu et al.'s research on Melanoma A375 cells (Bing-yu et al., 2016) and glioma U87 (Wei et al., 2020) cells shows that Naringin can reduce the level of mitotic protein kinase CDK4/CDK6 to inhibit its proliferation; Ruiying et al. (Rui-ying et al., 2022) found that Naringin inhibits the proliferation of cervical cancer ME-180 cells by increasing the expression of miR-628-5p; Zhou et al. (Zhou et al., 2019) showed that Naringin can also play a role in inhibiting the growth of Thyroid neoplasm. Here, CDK4 is linked to cervical carcinoma.